Literature DB >> 15867030

Early-onset group B streptococcal disease in the era of maternal screening.

Karen M Puopolo1, Lawrence C Madoff, Eric C Eichenwald.   

Abstract

BACKGROUND: With the widespread implementation of intrapartum antibiotic prophylaxis (IAP), the rate of early-onset neonatal sepsis and meningitis caused by Streptococcus agalactiae (group B streptococcus [GBS]) has decreased dramatically, especially in term infants. However, cases of GBS disease continue to occur despite IAP and incur significant morbidity and mortality. Inaccurate screening results, improper implementation of IAP, or antibiotic failure all may contribute to persistent disease.
OBJECTIVE: To determine if clinical, procedural, or microbiologic factors influenced persistent early-onset GBS disease (EOGBS) cases in a single large maternity service after the institution of a screening-based protocol for IAP.
METHODS: Retrospective review of all cases of culture-proven EOGBS at the Brigham and Women's Hospital (Boston, MA) from 1997 to 2003. Serotyping and surface protein analyses were performed on available disease isolates.
RESULTS: A total of 67260 infants were live-born during this period. Twenty-five cases of EOGBS (0.37 of 1000 live births) were identified. The overall incidence of EOGBS progressively decreased with different approaches to IAP. Of the 25 cases identified after institution of a screening-based protocol, 17 (68%) occurred in term infants (1 death), and 8 (32%) occurred in preterm infants (3 deaths). Among the mothers of term infants, 14 of 17 (82%) had been screened GBS negative; 1 was GBS unknown. More than half of the mothers of term infants who had screened GBS negative (8 of 14) had intrapartum risk factors for neonatal infection but did not receive antibiotics before delivery. Ten of the 17 term infants were evaluated for infection because of clinical signs of illness, and the remainder were evaluated because of intrapartum sepsis risk factors. Of the mothers of preterm infants, by the time of delivery 3 of 8 had been documented as GBS positive, 2 of 8 had been documented GBS negative, and 3 of 8 remained unknown. Only 1 of 25 women received adequate IAP, but the isolate was resistant to the administered antibiotic (clindamycin). Antibiotic resistance was not a factor in any other case, and no dominant serovariant was identified among tested isolates. Procedural errors (lack of recognition of documented GBS colonization or failure to evaluate infants at risk for sepsis) were identified in 4 cases.
CONCLUSIONS: The majority of the remaining cases of EOGBS occurred in infants whose mothers screened negative for GBS colonization. Even in the setting of a maternal GBS-screening program, efforts to evaluate and treat infants with intrapartum clinical risk factors for early-onset sepsis remain important. Until effective vaccines against GBS are available for clinical use, development and implementation of rapid and sensitive techniques for screening for GBS status and antibiotic susceptibility at presentation may help prevent additional cases of invasive GBS disease.

Entities:  

Mesh:

Year:  2005        PMID: 15867030     DOI: 10.1542/peds.2004-2275

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  55 in total

1.  Adherence to perinatal group B streptococcal prevention guidelines.

Authors:  William P Goins; Thomas R Talbot; William Schaffner; Kathryn M Edwards; Allen S Craig; Stephanie J Schrag; Melissa K Van Dyke; Marie R Griffin
Journal:  Obstet Gynecol       Date:  2010-06       Impact factor: 7.661

2.  Use of the complete blood cell count in early-onset neonatal sepsis.

Authors:  Christoph P Hornik; Daniel K Benjamin; Kristian C Becker; Daniel K Benjamin; Jennifer Li; Reese H Clark; Michael Cohen-Wolkowiez; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2012-08       Impact factor: 2.129

3.  Culture-based methods for detection and identification of Streptococcus agalactiae in pregnant women--what are we missing?

Authors:  A Adler; C Block; D Engelstein; D Hochner-Celnikcier; R Drai-Hassid; A E Moses
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-21       Impact factor: 3.267

Review 4.  Molecular-based screening for perinatal group B streptococcal infection: implications for prevention and therapy.

Authors:  Stéphane Emonet; Jacques Schrenzel; Begoña Martinez de Tejada
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

5.  Intrapartum group B Streptococcus screening in the labor ward by Xpert® GBS real-time PCR.

Authors:  C Plainvert; F El Alaoui; A Tazi; C Joubrel; O Anselem; M Ballon; A Frigo; C Branger; L Mandelbrot; F Goffinet; C Poyart
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-29       Impact factor: 3.267

6.  Real-time polymerase chain reaction for the rapid detection of group B streptococcal colonization in neonates.

Authors:  Girija Natarajan; Yvette R Johnson; Fan Zhang; Kang Mei Chen; Maria J Worsham
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

7.  Invasive group B streptococcus (GBS) disease in Norway 1996-2006.

Authors:  H Bergseng; M Rygg; L Bevanger; K Bergh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-17       Impact factor: 3.267

8.  Clindamycin-resistant group B Streptococcus and failure of intrapartum prophylaxis to prevent early-onset disease.

Authors:  Anne J Blaschke; Laurie S Pulver; E Kent Korgenski; Lucy A Savitz; Judy A Daly; Carrie L Byington
Journal:  J Pediatr       Date:  2010-01-13       Impact factor: 4.406

9.  Evolving microbiological epidemiology and high fetal mortality in 135 cases of bacteremia during pregnancy and postpartum.

Authors:  L Surgers; N Valin; B Carbonne; E Bingen; V Lalande; J Pacanowski; M-C Meyohas; P-M Girard; J-L Meynard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-21       Impact factor: 3.267

Review 10.  Group B Streptococcus vaccine: state of the art.

Authors:  Annalisa Nuccitelli; C Daniela Rinaudo; Domenico Maione
Journal:  Ther Adv Vaccines       Date:  2015-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.